Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Burning Rock Biotech (BNR) EBT Margin (2020 - 2025)

Historic EBT Margin for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to 12.58%.

  • Burning Rock Biotech's EBT Margin rose 150600.0% to 12.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 21.23%, marking a year-over-year increase of 619400.0%. This contributed to the annual value of 66.06% for FY2024, which is 551300.0% up from last year.
  • Burning Rock Biotech's EBT Margin amounted to 12.58% in Q3 2025, which was up 150600.0% from 6.37% recorded in Q2 2025.
  • Burning Rock Biotech's EBT Margin's 5-year high stood at 6.37% during Q2 2025, with a 5-year trough of 200.29% in Q2 2022.
  • For the 5-year period, Burning Rock Biotech's EBT Margin averaged around 110.56%, with its median value being 133.09% (2023).
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -923200bps in 2021, then soared by 1108700bps in 2023.
  • Over the past 5 years, Burning Rock Biotech's EBT Margin (Quarter) stood at 171.22% in 2021, then increased by 12bps to 150.68% in 2022, then grew by 12bps to 133.09% in 2023, then surged by 55bps to 60.29% in 2024, then surged by 79bps to 12.58% in 2025.
  • Its EBT Margin stands at 12.58% for Q3 2025, versus 6.37% for Q2 2025 and 9.98% for Q1 2025.